Journal article
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Blood, Vol.118(15), pp.4053-4061
10/13/2011
DOI: 10.1182/blood-2011-02-336990
PMCID: PMC3204728
PMID: 21673350
Abstract
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated DLBCL. A secondary aim was to assess the efficacy of interim positron emission tomography (PET) to predict outcome in DLBCL. Standard R-CHOP with the addition of E 360 mg/m
2
intravenously was administered for 6 cycles. A total of 107 patients were enrolled in the study. Toxicity was similar to standard R-CHOP. Overall response rate in the 81 eligible patients was 96% (74% CR/CRu) by computed tomography scan and 88% by PET. By intention to treat analysis, at a median follow-up of 43 months, the event-free survival (EFS) and overall survival (OS) at 3 years in all 107 patients were 70% and 80%, respectively. Interim PET was not associated with EFS or OS. Comparison with a cohort of 215 patients who were treated with R-CHOP showed an improved EFS in the ER-CHOP patients. ER-CHOP is well tolerated and results appear promising as a combination therapy. This study was registered at
www.clinicaltrials.gov
as #NCT00301821.
Details
- Title: Subtitle
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- Creators
- Ivana N. M Micallef - Mayo Clinic Rochester, Rochester, MNMatthew J Maurer - Mayo Clinic Rochester, Rochester, MNGregory A Wiseman - Mayo Clinic Rochester, Rochester, MNDaniel A Nikcevich - Duluth Community Clinical Oncology Program, Duluth, MNPaul J Kurtin - Mayo Clinic Rochester, Rochester, MNMichael W Cannon - Cancer Center of Kansas, Wichita, KSDomingo G Perez - Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MNGamini S Soori - Missouri Valley Cancer Consortium, Omaha, NE; andBrian K Link - University of Iowa Hospitals and Clinics, Iowa City, IAThomas M Habermann - Mayo Clinic Rochester, Rochester, MNThomas E Witzig - Mayo Clinic Rochester, Rochester, MN
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.118(15), pp.4053-4061
- Publisher
- American Society of Hematology
- DOI
- 10.1182/blood-2011-02-336990
- PMID
- 21673350
- PMCID
- PMC3204728
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Grant note
- P50 CA97274 / National Institutes of Health
- Language
- English
- Date published
- 10/13/2011
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094321702771
Metrics
13 Record Views